## **Condensed Consolidated Statement of Earnings**

(Unaudited; in Millions Except Per Share Figures)

	2011					Percent	
			Percent			Percent	Increase
		Amount	to Sales		Amount	t to Sales	(Decrease)
Sales to customers	\$	16,597	100.0	\$	15,330	100.0	8.3
Cost of products sold		5,172	31.2		4,630	30.2	11.7
Selling, marketing and administrative expenses		5,215	31.4		4,756	31.0	9.7
Research and development expense		1,882	11.3		1,648	10.8	14.2
Interest (income)expense, net		111	0.7		58	0.4	
Other (income)expense, net		206	1.3		18	0.1	
Restructuring expense		589	3.5				
Earnings before provision for taxes on income		3,422	20.6		4,220	27.5	(18.9)
Provision for taxes on income		646	3.9		771	5.0	(16.2)
Net earnings	\$	2,776	16.7	\$	3,449	22.5	(19.5)
Net earnings per share (Diluted)	\$	1.00		\$	1.23		(18.7)
Net earnings per share (Sharea)	Ψ	1.00		Ψ	1.20		(10.1)
Average shares outstanding (Diluted)		2,781.3			2,796.0		
Effective tax rate		18.9 %	, ,		18.3	%	
Adjusted earnings before provision for taxes and net earnings							
Earnings before provision for taxes on income	\$	4,413 (1	1) 26.6	\$	4,377	(2) 28.6	0.8
Net earnings	\$	3,548 (1	1) 21.4	\$	3,382	(2) 22.1	4.9
Net earnings per share (Diluted)	\$	1.28 (1	1)	\$	1.21	(2)	5.8
Effective tax rate		19.6 %	, D		22.7	<b>7</b> %	

SECOND QUARTER

<sup>(1)</sup> The \$991 million difference between as reported earnings and as adjusted earnings before provision for taxes on income is the exclusion of expense due to restructuring (\$676 million, of which \$589 million is reported as restructuring expense and \$87 million is included in cost of products sold), expense due to litigation matters (\$363 million), additional DePuy ASR™ Hip recall costs (\$54 million) and a mark-to-market gain associated with a currency option related to the planned acquisition of Synthes (\$102 million). Net earnings and net earnings per share (diluted) on these items are \$772 million and \$0.28 per share, respectively.

<sup>(2)</sup> The difference between as reported and as adjusted earnings before provision for taxes on income, net earnings and net earnings per share (diluted) is the exclusion of net litigation expense of \$157 million before tax, net litigation income of \$67 million after tax and \$0.02 per share, respectively.

## **Condensed Consolidated Statement of Earnings**

(Unaudited; in Millions Except Per Share Figures)

(Criaconos, in minorio Encopri. or Criaco : iganos)	,									
	2011					Percent				
			Percent				Percent	Increase		
		Amount	to Sales		Amount		to Sales	(Decrease)		
Sales to customers	\$	32,770	100.0	\$	30,961		100.0	5.8		
Cost of products sold		9,950	30.4		9,158		29.6	8.6		
Selling, marketing and administrative expenses		10,271	31.3		9,535		30.8	7.7		
Research and development expense		3,620	11.0		3,205		10.4	12.9		
Interest (income)expense, net		215	0.7		139		0.4			
Other (income)expense, net		193	0.6		(1,576)	)	(5.1)			
Restructuring expense		589	1.8		-		-			
Earnings before provision for taxes on income		7,932	24.2		10,500		33.9	(24.5)		
Provision for taxes on income		1,680	5.1		2,525		8.1	(33.5)		
Net earnings	\$	6,252	19.1	\$	7,975		25.8	(21.6)		
Net earnings per share (Diluted)	\$	2.25		\$	2.85			(21.1)		
Average shares outstanding (Diluted)		2,778.1			2,796.1					
Effective tax rate		21.2 %			24.0	%				
Adjusted earnings before provision for taxes and net earnings										
Earnings before provision for taxes on income	\$	9,269 (1)	28.3	\$	9,160	(2)	29.6	1.2		
Net earnings	\$	7,295 (1)	22.3	\$	6,998	(2)	22.6	4.2		
Net earnings per share (Diluted)	\$	2.63 (1)		\$	2.50	(2)		5.2		
Effective tax rate		21.3 %			23.6	%				

SIX MONTHS

<sup>(1)</sup> The \$1,337 million difference between as reported earnings and as adjusted earnings before provision for taxes on income is the exclusion of expense due to restructuring (\$676 million, of which \$589 million is reported as restructuring expense and \$87 million is included in cost of products sold), expense due to litigation matters (\$654 million), additional DePuy ASR<sup>TM</sup> Hip recall costs (\$109 million) and a mark-to-market gain associated with a currency option related to the planned acquisition of Synthes (\$102 million). Net earnings and net earnings per share (diluted) on these items are \$1,043 million and \$0.38 per share, respectively.

<sup>(2)</sup> The difference between as reported earnings and as adjusted earnings before provision for taxes on income, net earnings and net earnings per share (diluted) is the exclusion of income from net litigation of \$1,340 million, \$977 million and \$0.35 per share, respectively.